1-10 of 10
Shulamit Wittebol
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial

Arnon P. Kater, MD, Marinus H.J. H.J. Van Oers, MD PhD, Yvette Norden, Roberto D. Liu, Martin R. Schipperus, Martine Chamuleau, MD PhD, Marcel Nijland, MD, Jeanette K. Doorduijn, MD PhD, Michel van Gelder, MDPhD, Mels Hoogendoorn, MDPhD, Fransien Croon-de Boer, Shulamit Wittebol, Martijn Kerst, MDPhD, Willem Marijt, Ward Posthuma, MD PhD, Reinier Raymakers, MDPhD, Ron Schaafsma, MDPhD, Johan Dobber, Sabina Kersting, MDPhD, Mark-David Levin
Journal: Blood
Blood (2017) 130 (Supplement 1): 4328.
https://doi.org/10.1182/blood.V130.Suppl_1.4328.4328
Published: 2017
Journal Articles

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Pieter Sonneveld, MD, Ph.D, Christof Scheid, MD, Bronno van der Holt, Laila el Jarari, Uta Bertsch, MD, Hans Salwender, MD, Sonja Zweegman, MD PhD, Edo Vellenga, Annemiek Broyl, Igor Wolfgang Blau, MD, PhD, Katja Weisel, MD, Shulamit Wittebol, Gerard M.J. Bos, Prof MD PhD, Marjan Stevens, Ingo GH Schmidt-Wolf, MD, Michael Pfreundschuh, MD, Dirk Hose, Dr. med. dipl.-phys., Anna Jauch, PhD, Helgi van de Velde, Reinier Raymakers, MD, PhD, Martyn Ronald Schaafsma, Marie Jose Kersten, MD, PhD, Marinus van Marwijk Kooy, MD, PhD, Ulrich Duehrsen, MD, Hans Walter Lindemann, MD, Pierre W. Wijermans, MD, PhD, Henk Lokhorst, H. Goldschmidt
Journal: Blood
Blood (2013) 122 (21): 404.
https://doi.org/10.1182/blood.V122.21.404.404
Published: 2013
Journal Articles

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Pieter Sonneveld, Ingo Schmidt-Wolf, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Edo Vellenga, Joerg Schubert, Igor Wolfgang Blau, Asiong Jie, Berna Beverloo, Dirk Hose, Anna Jauch, Helgi van de Velde, Martijn Schaafsma, Walter Lindemann, Marie Jose Kersten, Ulrich Duehrsen, MD, Michel Delforge, Katja Weisel, Sandra Croockewit, Hans Martin, Shulamit Wittebol, Christof Scheid, Gerard Bos, Marinus van Marwijk-Kooy, Pierre Wijermans, Henk Lokhorst, Hartmut Goldschmidt
Journal: Blood
Blood (2010) 116 (21): 40.
https://doi.org/10.1182/blood.V116.21.40.40
Published: 2010
Journal Articles

Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma

Christof Scheid, Pieter Sonneveld, Ingo Schmidt-Wolf, Bronno van der Holt, Thomas Hielscher, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Mathias Hänel, Edo Vellenga, Joerg Schubert, Igor Wolfgang Blau, Asiong Jie, Helgi Van de elde, Norma Peter, Martijn Schaafsma, Walter Lindemann, Marie Jose Kersten, Ulrich Duehrsen, Michel Delforge, Katja Weisel, Sandra Croockewit, Hans Martin, Shulamit Wittebol, Harry Schouten, Marinus van Marwijk-Kooy, Pierre Wijermans, Henk M Lokhorst, Hartmut Goldschmidt
Journal: Blood
Blood (2010) 116 (21): 2396.
https://doi.org/10.1182/blood.V116.21.2396.2396
Published: 2010
Journal Articles

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

Jan J. Cornelissen, Bronno van der Holt, Gregor E. G. Verhoef, Mars B. van 't Veer, Marinus H. J. van Oers, Harry C. Schouten, Gert Ossenkoppele, Pieter Sonneveld, Johan Maertens, Marinus van Marwijk Kooy, Martijn R. Schaafsma, Pierre W. Wijermans, Douwe H. Biesma, Shulamit Wittebol, Paul J. Voogt, Joke W. Baars, Pierre Zachée, Leo F. Verdonck, Bob Löwenberg, Adriaan W. Dekker
Journal: Blood
Blood (2009) 113 (6): 1375–1382.
https://doi.org/10.1182/blood-2008-07-168625
Published: 2009
Includes: Supplemental data
Journal Articles

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

Clinical Trials & Observations
Wendy Deenik, Bronno van der Holt, Gregor E. G. Verhoef, Willem M. Smit, Marie J. Kersten, Hanneke C. Kluin-Nelemans, Leo F. Verdonck, Augustin Ferrant, Anton V. M. B. Schattenberg, Jeroen J. W. M. Janssen, Pieter Sonneveld, Marinus van Marwijk Kooy, Shulamit Wittebol, Roelof Willemze, Pierre W. Wijermans, Petra H. M. Westveer, H. Berna Beverloo, Peter Valk, Bob Löwenberg, Gert J. Ossenkoppele, Jan J. Cornelissen
Journal: Blood
Blood (2008) 111 (5): 2581–2588.
https://doi.org/10.1182/blood-2007-08-107482
Published: 2008
Journal Articles

In Vivo Tumor Dynamic Studies in Stable CLL Show an Association between CLL Turnover Rates and IgV H Mutational Status and Provide Evidence That the Bone Marrow Is Not a Major Site of Neoplastic Cell Generation.

Arnon P. Kater, MD, PhD, Rogier van Gent, Annelieke Jaspers, Jose A.M. Borghans, PhD, Sigrid Otto, An F.C. Ruiter, Shulamit Wittebol, MD, Eric Eldering, PhD, Marinus H.J. Van Oers, MD, PhD, Marie-Jose Kersten, MD, PhD, Frank Miedema, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 1128.
https://doi.org/10.1182/blood.V110.11.1128.1128
Published: 2007
Journal Articles

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Updated Analysis of the Randomized Phase III Study HOVON 24 MM.

Pieter Sonneveld, Bronno van der Holt, Christine Segeren, Edo Vellenga, Reinier Raymakers, Gregor Verhoef, Ron Schaafsma, Marinus van Oers, Pierre Weijermans, Wim Fibbe, Shulamit Wittebol, Marinus van Marwijk, Douwe Biesma, Joke Baars, Harry Schouten, Petra Westveer, Monique Steijaert, Henk Lokhorst
Journal: Blood
Blood (2004) 104 (11): 948.
https://doi.org/10.1182/blood.V104.11.948.948
Published: 2004
Journal Articles

High Rates of Molecular Response and Low Incidence of Mutations in Patients Treated with Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated with a Dose-Escalated Combination of Imatinib and Cytarabin.

Jan J. Cornelissen, MD, PhD, Peter Valk, PhD, Gregor E.G. Verhoef, MD, PhD, Wim M. Smit, MD, PhD, Marinus van Marwijk-Kooij, MD, PhD, Shulamit Wittebol, MD, Marinus H.J. van Oers, MD, PhD, Hanneke C. Kluin-Nelemans, MD, PhD, Bob Lowenberg, MD, PhD, Roelof Willemze, MD, PhD, Antonius V.M.B. Schattenberg, MD, PhD, Gert Ossenkoppele, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 19.
https://doi.org/10.1182/blood.V104.11.19.19
Published: 2004
Journal Articles

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

Clinical Trials & Observations
Christine M. Segeren, Pieter Sonneveld, Bronno van der Holt, Edo Vellenga, Alexandra J. Croockewit, Gregor E. G. Verhoef, Jan J. Cornelissen, Martijn R. Schaafsma, Marinus H. J. van Oers, Pierre W. Wijermans, Wim E. Fibbe, Shulamit Wittebol, Harry C. Schouten, Marinus van Marwijk Kooy, Douwe H. Biesma, Joke W. Baars, Rosalyn Slater, Monique M. C. Steijaert, Ivon Buijt, Henk M. Lokhorst
Journal: Blood
Blood (2003) 101 (6): 2144–2151.
https://doi.org/10.1182/blood-2002-03-0889
Published: 2003